Copy to clipboard 
Medacta reported 2H23 orthopedic sales of EUR 255.6 million ($276 million USD), +13.2% compared to the second half of 2022. The company generated EUR 510.8 million ($551.6 million USD) in 2023, growing 16.9% compared to the prior year.
The company’s joint replacement growth is well above market average, which is especially impressive considering only a portion of its sales come from the U.S. and Australia where backlogged procedures drove elevated volumes in 2023. Medacta’s knee replacement sales eclipsed $200 million in sales during the year, driven by its personalized kinematic alignment solutions.
“Knee replacement is experiencing tremendous growth and this is directly linked to our new approach to total knee replacement with kinematic alignment,” said Medacta CEO Francesco Siccardi. “It is finally gaining what we believe is the right reputation and very rapidly becoming the new standard. It is a prominent topic in all knee symposia worldwide and Medacta has been pioneering this approach.”
The success of kinematic alignment in knees, the AMIS hip approach and the Medacata Shoulder System made the company the sixth-largest joint replacement company by revenue and the 11th-largest orthopedic company overall.
The company’s strongest regional growth in 2023 came in EMEA, which grew more than 23%. The robustness of Medacta’s supply chain, supported by a new distribution center in Memphis and its Swiss plants’ expansion, allowed it to meet demand and pick up some additional opportunities.
Medacta is targeting constant currency growth in the range of 13% to 15% for 2024.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| 2H23 | 2H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $246.0 | $217.1 | $28.9 | 13.3% |
| Knees | $107.8 | $94.2 | $13.6 | 14.4% |
| Hips | $120.0 | $108.2 | $11.8 | 10.9% |
| Extremities | $18.2 | $14.7 | $3.5 | 24% |
| Spine | $25.2 | $22.9 | $2.3 | 10.1% |
| Sports Medicine | $1.1 | $0.7 | $0.4 | 60.6% |
| Enabling Technology | $3.7 | $3.3 | $0.4 | 12.9% |
| Total | $276.0 | $243.9 | $32.1 | 13.2% |
| FY23 | FY22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $493.3 | $420.7 | $72.6 | 17.3% |
| Knees | $214.2 | $177.6 | $36.6 | 20.6% |
| Hips | $243.2 | $215.5 | $27.7 | 12.9% |
| Extremities | $35.9 | $27.6 | $8.3 | 30.2% |
| Spine | $48.8 | $43.7 | $5.1 | 11.7% |
| Sports Medicine | $2.2 | $1.3 | $0.9 | 68.7% |
| Enabling Technology | $7.4 | $6.4 | $1.0 | 15.3% |
| Total | $551.6 | $472.1 | $79.5 | 16.9% |
Orthopedic Sales by Geography
| 2H23 | 2H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Americas | $90.1 | $84.3 | $5.8 | 6.9% |
| North America | $83.7 | $78.4 | $5.3 | 6.8% |
| Latin America | $6.4 | $6.0 | $0.5 | 7.9% |
| Other | $185.9 | $159.6 | $26.3 | 16.5% |
| EMEA | $128.9 | $106.1 | $22.8 | 21.5% |
| APAC | $57.0 | $53.5 | $3.5 | 6.5% |
| Total | $276.0 | $243.9 | $32.1 | 13.2% |
| FY23 | FY22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Americas | $177.3 | $157.8 | $19.5 | 12.4% |
| North America | $166.3 | $147.7 | $18.6 | 12.6% |
| Latin America | $11.0 | $10.1 | $0.9 | 9% |
| Other | $374.3 | $314.3 | $60.0 | 19.1% |
| EMEA | $261.8 | $212.4 | $49.4 | 23.3% |
| APAC | $112.5 | $101.9 | $10.6 | 10.4% |
| Total | $551.6 | $472.1 | $79.5 | 16.9% |
Medacta reported 2H23 orthopedic sales of EUR 255.6 million ($276 million USD), +13.2% compared to the second half of 2022. The company generated EUR 510.8 million ($551.6 million USD) in 2023, growing 16.9% compared to the prior year.
The company's joint replacement growth is well above market average, which is especially impressive...
Medacta reported 2H23 orthopedic sales of EUR 255.6 million ($276 million USD), +13.2% compared to the second half of 2022. The company generated EUR 510.8 million ($551.6 million USD) in 2023, growing 16.9% compared to the prior year.
The company’s joint replacement growth is well above market average, which is especially impressive considering only a portion of its sales come from the U.S. and Australia where backlogged procedures drove elevated volumes in 2023. Medacta’s knee replacement sales eclipsed $200 million in sales during the year, driven by its personalized kinematic alignment solutions.
“Knee replacement is experiencing tremendous growth and this is directly linked to our new approach to total knee replacement with kinematic alignment,” said Medacta CEO Francesco Siccardi. “It is finally gaining what we believe is the right reputation and very rapidly becoming the new standard. It is a prominent topic in all knee symposia worldwide and Medacta has been pioneering this approach.”
The success of kinematic alignment in knees, the AMIS hip approach and the Medacata Shoulder System made the company the sixth-largest joint replacement company by revenue and the 11th-largest orthopedic company overall.
The company’s strongest regional growth in 2023 came in EMEA, which grew more than 23%. The robustness of Medacta’s supply chain, supported by a new distribution center in Memphis and its Swiss plants’ expansion, allowed it to meet demand and pick up some additional opportunities.
Medacta is targeting constant currency growth in the range of 13% to 15% for 2024.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| 2H23 | 2H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $246.0 | $217.1 | $28.9 | 13.3% |
| Knees | $107.8 | $94.2 | $13.6 | 14.4% |
| Hips | $120.0 | $108.2 | $11.8 | 10.9% |
| Extremities | $18.2 | $14.7 | $3.5 | 24% |
| Spine | $25.2 | $22.9 | $2.3 | 10.1% |
| Sports Medicine | $1.1 | $0.7 | $0.4 | 60.6% |
| Enabling Technology | $3.7 | $3.3 | $0.4 | 12.9% |
| Total | $276.0 | $243.9 | $32.1 | 13.2% |
| FY23 | FY22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $493.3 | $420.7 | $72.6 | 17.3% |
| Knees | $214.2 | $177.6 | $36.6 | 20.6% |
| Hips | $243.2 | $215.5 | $27.7 | 12.9% |
| Extremities | $35.9 | $27.6 | $8.3 | 30.2% |
| Spine | $48.8 | $43.7 | $5.1 | 11.7% |
| Sports Medicine | $2.2 | $1.3 | $0.9 | 68.7% |
| Enabling Technology | $7.4 | $6.4 | $1.0 | 15.3% |
| Total | $551.6 | $472.1 | $79.5 | 16.9% |
Orthopedic Sales by Geography
| 2H23 | 2H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Americas | $90.1 | $84.3 | $5.8 | 6.9% |
| North America | $83.7 | $78.4 | $5.3 | 6.8% |
| Latin America | $6.4 | $6.0 | $0.5 | 7.9% |
| Other | $185.9 | $159.6 | $26.3 | 16.5% |
| EMEA | $128.9 | $106.1 | $22.8 | 21.5% |
| APAC | $57.0 | $53.5 | $3.5 | 6.5% |
| Total | $276.0 | $243.9 | $32.1 | 13.2% |
| FY23 | FY22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Americas | $177.3 | $157.8 | $19.5 | 12.4% |
| North America | $166.3 | $147.7 | $18.6 | 12.6% |
| Latin America | $11.0 | $10.1 | $0.9 | 9% |
| Other | $374.3 | $314.3 | $60.0 | 19.1% |
| EMEA | $261.8 | $212.4 | $49.4 | 23.3% |
| APAC | $112.5 | $101.9 | $10.6 | 10.4% |
| Total | $551.6 | $472.1 | $79.5 | 16.9% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
